Logo image of STIM

NEURONETICS INC (STIM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:STIM - US64131A1051 - Common Stock

1.42 USD
-0.07 (-4.7%)
Last: 12/1/2025, 5:50:54 PM
1.429 USD
+0.01 (+0.63%)
After Hours: 12/1/2025, 5:50:54 PM
Fundamental Rating

3

Taking everything into account, STIM scores 3 out of 10 in our fundamental rating. STIM was compared to 188 industry peers in the Health Care Equipment & Supplies industry. STIM has a bad profitability rating. Also its financial health evaluation is rather negative. STIM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year STIM has reported negative net income.
In the past year STIM has reported a negative cash flow from operations.
In the past 5 years STIM always reported negative net income.
In the past 5 years STIM always reported negative operating cash flow.
STIM Yearly Net Income VS EBIT VS OCF VS FCFSTIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

STIM has a Return On Assets of -30.59%. This is comparable to the rest of the industry: STIM outperforms 44.15% of its industry peers.
With a Return On Equity value of -162.68%, STIM is not doing good in the industry: 68.62% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -30.59%
ROE -162.68%
ROIC N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
STIM Yearly ROA, ROE, ROICSTIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

The Gross Margin of STIM (50.43%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of STIM has remained more or less at the same level.
STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
STIM Yearly Profit, Operating, Gross MarginsSTIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STIM has more shares outstanding
STIM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for STIM has been reduced compared to a year ago.
STIM Yearly Shares OutstandingSTIM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
STIM Yearly Total Debt VS Total AssetsSTIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -3.41, we must say that STIM is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.41, STIM is doing worse than 65.43% of the companies in the same industry.
STIM has a Debt/Equity ratio of 2.40. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.40, STIM is not doing good in the industry: 83.51% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.4
Debt/FCF N/A
Altman-Z -3.41
ROIC/WACCN/A
WACC8.78%
STIM Yearly LT Debt VS Equity VS FCFSTIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 2.24 indicates that STIM has no problem at all paying its short term obligations.
The Current ratio of STIM (2.24) is worse than 60.11% of its industry peers.
A Quick Ratio of 2.09 indicates that STIM has no problem at all paying its short term obligations.
STIM has a Quick ratio of 2.09. This is comparable to the rest of the industry: STIM outperforms 52.66% of its industry peers.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 2.09
STIM Yearly Current Assets VS Current LiabilitesSTIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

STIM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.33%, which is quite impressive.
The Revenue has grown by 78.62% in the past year. This is a very strong growth!
Measured over the past years, STIM shows a small growth in Revenue. The Revenue has been growing by 3.63% on average per year.
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.45%
Revenue 1Y (TTM)78.62%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%101.28%

3.2 Future

STIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.70% yearly.
STIM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.89% yearly.
EPS Next Y57.31%
EPS Next 2Y29.23%
EPS Next 3Y21.45%
EPS Next 5Y18.7%
Revenue Next Year109.15%
Revenue Next 2Y52.89%
Revenue Next 3Y38.05%
Revenue Next 5Y26.89%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
STIM Yearly Revenue VS EstimatesSTIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M 200M
STIM Yearly EPS VS EstimatesSTIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STIM Price Earnings VS Forward Price EarningsSTIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STIM Per share dataSTIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

STIM's earnings are expected to grow with 21.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.23%
EPS Next 3Y21.45%

More info and screens

0

5. Dividend

5.1 Amount

STIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEURONETICS INC

NASDAQ:STIM (12/1/2025, 5:50:54 PM)

After market: 1.429 +0.01 (+0.63%)

1.42

-0.07 (-4.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners27.71%
Inst Owner Change16.37%
Ins Owners6.38%
Ins Owner Change6.03%
Market Cap97.26M
Revenue(TTM)129.87M
Net Income(TTM)-44.50M
Analysts82.22
Price Target6.63 (366.9%)
Short Float %14.13%
Short Ratio3.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.21%
Min EPS beat(2)-91.81%
Max EPS beat(2)-0.62%
EPS beat(4)0
Avg EPS beat(4)-52.8%
Min EPS beat(4)-91.81%
Max EPS beat(4)-0.62%
EPS beat(8)2
Avg EPS beat(8)-34.41%
EPS beat(12)5
Avg EPS beat(12)-16.74%
EPS beat(16)8
Avg EPS beat(16)-9.34%
Revenue beat(2)1
Avg Revenue beat(2)-0.93%
Min Revenue beat(2)-3.39%
Max Revenue beat(2)1.52%
Revenue beat(4)3
Avg Revenue beat(4)4.57%
Min Revenue beat(4)-3.39%
Max Revenue beat(4)12.31%
Revenue beat(8)4
Avg Revenue beat(8)-0.03%
Revenue beat(12)6
Avg Revenue beat(12)0.44%
Revenue beat(16)10
Avg Revenue beat(16)1.37%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-14.29%
EPS NQ rev (3m)-14.29%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-5.55%
Revenue NQ rev (3m)-5.55%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.75
P/FCF N/A
P/OCF N/A
P/B 3.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS1.9
BVpS0.4
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.59%
ROE -162.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.43%
FCFM N/A
ROA(3y)-29.62%
ROA(5y)-29.17%
ROE(3y)-103.71%
ROE(5y)-91.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y-0.84%
F-Score3
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 2.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 21.44%
Cap/Sales 0.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 2.09
Altman-Z -3.41
F-Score3
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)129%
Cap/Depr(5y)137.27%
Cap/Sales(3y)3.43%
Cap/Sales(5y)3.2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.45%
EPS Next Y57.31%
EPS Next 2Y29.23%
EPS Next 3Y21.45%
EPS Next 5Y18.7%
Revenue 1Y (TTM)78.62%
Revenue growth 3Y10.63%
Revenue growth 5Y3.63%
Sales Q2Q%101.28%
Revenue Next Year109.15%
Revenue Next 2Y52.89%
Revenue Next 3Y38.05%
Revenue Next 5Y26.89%
EBIT growth 1Y-23.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.12%
EBIT Next 3Y22.25%
EBIT Next 5Y13.76%
FCF growth 1Y22.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.83%
OCF growth 3YN/A
OCF growth 5YN/A

NEURONETICS INC / STIM FAQ

What is the ChartMill fundamental rating of NEURONETICS INC (STIM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to STIM.


Can you provide the valuation status for NEURONETICS INC?

ChartMill assigns a valuation rating of 1 / 10 to NEURONETICS INC (STIM). This can be considered as Overvalued.


Can you provide the profitability details for NEURONETICS INC?

NEURONETICS INC (STIM) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for STIM stock?

The Earnings per Share (EPS) of NEURONETICS INC (STIM) is expected to grow by 57.31% in the next year.